Floatz logo

Autologous Human Tumor-Derived Hsppc-96

Lymphoma, Follicular

Agenus Inc.vaccinePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

210 Active assets in the Lymphoma, Follicular cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2/3BBB
Romidepsin
City of Hope Medical Center
Phase 2BBB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
Recombinant Human Hyaluronidase
National Cancer Institute (NCI)
Phase 3BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Autologous Human Tumor-Derived Hsppc-96 is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative ·
57 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →